Stryker Corporation (NYSE:SYK) – Stock analysts at SunTrust Banks upped their Q2 2018 earnings per share (EPS) estimates for Stryker in a research note issued on Tuesday. SunTrust Banks analyst B. Nudell now anticipates that the medical technology company will post earnings per share of $1.70 for the quarter, up from their prior forecast of $1.69. SunTrust Banks currently has a “Buy” rating and a $179.00 price target on the stock. SunTrust Banks also issued estimates for Stryker’s Q1 2019 earnings at $1.73 EPS, Q2 2019 earnings at $1.86 EPS, Q3 2019 earnings at $1.82 EPS and Q4 2019 earnings at $2.39 EPS.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.55%. The firm had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis.

Several other research analysts have also recently commented on the stock. Oppenheimer restated a “hold” rating and issued a $165.00 target price on shares of Stryker in a research report on Thursday, February 1st. Citigroup restated a “market perform” rating and issued a $165.00 target price (up previously from $156.00) on shares of Stryker in a research report on Thursday, February 1st. They noted that the move was a valuation call. Guggenheim restated a “buy” rating on shares of Stryker in a research report on Wednesday, January 31st. Piper Jaffray Companies restated a “buy” rating and issued a $170.00 target price on shares of Stryker in a research report on Wednesday, January 31st. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $163.00 target price on shares of Stryker in a research report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $162.50.

Stryker (NYSE SYK) traded up $0.69 during midday trading on Thursday, reaching $148.70. 231,685 shares of the company’s stock traded hands, compared to its average volume of 1,434,909. Stryker has a 1 year low of $122.78 and a 1 year high of $170.00. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66. The company has a market cap of $57,509.09, a PE ratio of 23.68, a price-to-earnings-growth ratio of 2.21 and a beta of 0.70.

A number of large investors have recently modified their holdings of the stock. Arizona State Retirement System boosted its holdings in Stryker by 2.0% during the fourth quarter. Arizona State Retirement System now owns 110,481 shares of the medical technology company’s stock worth $17,107,000 after buying an additional 2,133 shares in the last quarter. State of Wisconsin Investment Board boosted its holdings in Stryker by 4.8% during the fourth quarter. State of Wisconsin Investment Board now owns 463,899 shares of the medical technology company’s stock worth $71,830,000 after buying an additional 21,439 shares in the last quarter. D.A. Davidson & CO. boosted its holdings in Stryker by 5.8% during the fourth quarter. D.A. Davidson & CO. now owns 46,749 shares of the medical technology company’s stock worth $7,239,000 after buying an additional 2,582 shares in the last quarter. Independence Bank of Kentucky bought a new stake in Stryker during the fourth quarter worth approximately $181,000. Finally, Advisory Services Network LLC boosted its holdings in Stryker by 319.6% during the fourth quarter. Advisory Services Network LLC now owns 14,167 shares of the medical technology company’s stock worth $2,194,000 after buying an additional 10,791 shares in the last quarter. Hedge funds and other institutional investors own 74.85% of the company’s stock.

In related news, VP William E. Berry, Jr. sold 1,306 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total transaction of $214,732.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $160.53, for a total transaction of $479,021.52. Following the sale, the insider now owns 9,100 shares of the company’s stock, valued at $1,460,823. The disclosure for this sale can be found here. Insiders sold 16,840 shares of company stock valued at $2,749,989 over the last quarter. Insiders own 7.40% of the company’s stock.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.26%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s dividend payout ratio (DPR) is presently 70.15%.

TRADEMARK VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2018/02/09/suntrust-banks-equities-analysts-increase-earnings-estimates-for-stryker-corporation-syk.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.